112 results on '"Swisher-McClure S"'
Search Results
2. Comparative assessment of radiation therapy–induced vasculitis using [18F]FDG-PET/CT in patients with non-small cell lung cancer treated with proton versus photon radiotherapy
- Author
-
Evanson, D., primary, Griffin, M., additional, O’Reilly, S. E., additional, Johnson, T., additional, Werner, T., additional, Kothekar, E., additional, Jahangiri, P., additional, Simone, C. B., additional, Swisher-McClure, S., additional, Feigenberg, S. J., additional, Revheim, M.-E., additional, Zou, J., additional, and Alavi, A., additional
- Published
- 2023
- Full Text
- View/download PDF
3. Comparative assessment of radiation therapy–induced vasculitis using [18F]FDG-PET/CT in patients with non-small cell lung cancer treated with proton versus photon radiotherapy.
- Author
-
Evanson, D., Griffin, M., O'Reilly, S. E., Johnson, T., Werner, T., Kothekar, E., Jahangiri, P., Simone 2nd, C. B., Swisher-McClure, S., Feigenberg, S. J., Revheim, M.-E., Zou, J., and Alavi, A.
- Subjects
NON-small-cell lung carcinoma ,PHOTON beams ,POSITRON emission tomography ,PHOTONS ,PROTONS ,THORACIC aorta - Abstract
Purpose: To assess radiation therapy (RT)-induced vasculitis in patients with non-small cell lung cancer (NSCLC) by examining changes in the uptake of
18 F-fluoro-D-deoxyglucose ([18 F]FDG) by positron emission tomography/computed tomography (PET/CT) images of the ascending aorta (AA), descending aorta (DA), and aortic arch (AoA) before and after proton and photon RT. Method: Thirty-five consecutive locally advanced NSCLC patients were definitively treated with proton (n = 27) or photon (n = 8) RT and concurrent chemotherapy. The patients were prospectively enrolled to undergo [18 F]FDG-PET/CT imaging before and 3 months after RT. An adaptive contrast-oriented thresholding algorithm was applied to generate mean standardized uptake values (SUVmean) for regions of interest (ROIs) 3 mm outside and 3 mm inside the outer perimeter of the AA, DA, and AoA. These ROIs were employed to exclusively select the aortic wall and remove the influence of blood pool activity. SUVmeans before and after RT were compared using two-tailed paired t-tests. Results: RT treatments were associated with increased SUVmeans in the AA, DA, and AoA—1.9%, 0.3%, and 1.3% for proton and 15.8%, 9.5%, and 15.5% for photon, respectively. There was a statistically significant difference in the ∆SUVmean (post-RT SUVmean − pre-RT SUVmean) in patients treated with photon RT when compared to ∆SUVmean in patients treated with proton RT in the AA (p = 0.043) and AoA (p = 0.015). There was an average increase in SUVmean that was related to dose for photon patients (across structures), but that was not seen for proton patients, although the increase was not statistically significant. Conclusion: Our results suggest that patients treated with photon RT for NSCLC may exhibit significantly more RT-induced inflammation (measured as ∆SUVmean) in the AA and AoA when compared to patients who received proton RT. Knowledge gained from further analyses in larger cohorts could aid in treatment planning and help prevent the significant morbidity and mortality associated with RT-induced vascular complications. Trial registration: NCT02135679. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
4. PO-0946 Inter-fraction robustness of DECT-based head and neck proton therapy with reduced range uncertainty margins
- Author
-
O'Reilly, S., primary, Cheng, C., additional, Lalonde, A., additional, Burgdorf, B., additional, Zou, W.J., additional, Yin, L., additional, Swisher-McClure, S., additional, Ghiam, A. Fotouhi, additional, Lukens, J.N., additional, Lin, A., additional, Dong, L., additional, and Teo, B.K.K., additional
- Published
- 2019
- Full Text
- View/download PDF
5. Proton Therapy Improves Toxicity for Oropharyngeal Cancer: An Outcomes and Predictive Model-based Approach
- Author
-
Rwigema, J. C., Langendijk, J. A., van der Laan, H. P., Lukens, J. N., Swisher-McClure, S. D., Lin, A., Damage and Repair in Cancer Development and Cancer Treatment (DARE), and Guided Treatment in Optimal Selected Cancer Patients (GUTS)
- Published
- 2017
6. SP-0340: Model-based clinical validation of proton therapy in head and neck cancer
- Author
-
Lin, A., primary, Rwigema, J.C., additional, Langendijk, J., additional, Lukens, J., additional, and Swisher-McClure, S., additional
- Published
- 2018
- Full Text
- View/download PDF
7. Beyond Positive Margins and Extracapsular Extension: Evaluating the Impact of Postoperative Chemoradiation Therapy in Locally Advanced Head and Neck Cancer
- Author
-
Trifiletti, D.M., primary, Lin, A., additional, Lukens, J.N., additional, Mendenhall, W.M., additional, Mitra, N., additional, Read, P.W., additional, and Swisher-Mcclure, S., additional
- Published
- 2016
- Full Text
- View/download PDF
8. Predictors of Receipt of Regional Nodal Irradiation in Patients With Pathologic Complete Response in the Axilla to Neoadjuvant Chemotherapy
- Author
-
Pham, Y.D., primary, Grover, S., additional, Badiyan, S.N., additional, Trifiletti, D.M., additional, Showalter, S., additional, Juloori, A., additional, Vicini, F., additional, Freedman, G.M., additional, Tendulkar, R.D., additional, Swisher-Mcclure, S., additional, Nichols, E.M., additional, Feigenberg, S.J., additional, and Shah, C.S., additional
- Published
- 2016
- Full Text
- View/download PDF
9. Low Rates of Adjuvant Radiation in Nonmetastatic Prostate Cancer Patients With Pathologic Risk Factors
- Author
-
Kalbasi, A., primary, Swisher-McClure, S., additional, Mitra, N., additional, Sunderland, R., additional, Smaldone, M., additional, Uzzo, R., additional, and Bekelman, J.E., additional
- Published
- 2014
- Full Text
- View/download PDF
10. Survival Outcomes of Patients With T4a Larynx Cancer Following Initial Management With Surgery Versus Larynx Preservation Therapy
- Author
-
Grover, S., primary, Swisher-McClure, S., additional, and Lin, A., additional
- Published
- 2014
- Full Text
- View/download PDF
11. SU-E-J-146: Effectiveness of Daily Endorectal Balloon for Post-Prostatectomy Patients Undergoing Pencil Beam Scanning Proton Therapy
- Author
-
Yin, L, primary, Vapiwala, N, additional, Sutton, D, additional, Ding, X, additional, Swisher-McClure, S, additional, Bui, V, additional, Deville, C, additional, Tochner, Z, additional, and Both, S, additional
- Published
- 2013
- Full Text
- View/download PDF
12. Radical Cystectomy (RC) Versus Bladder Preservation Therapy (BPT) for Muscle-invasive Bladder Cancer
- Author
-
Bekelman, J.E., primary, Handorf, E., additional, Guzzo, T., additional, Christodouleas, J., additional, Resnick, M., additional, Swisher-McClure, S., additional, Vaughn, D., additional, Pollack, C., additional, Polsky, D., additional, and Mitra, N., additional
- Published
- 2012
- Full Text
- View/download PDF
13. Radical Cystectomy (RC) versus Bladder Preservation Therapy (BPT): Influence of Stage Discrepancy on Comparative Effectiveness
- Author
-
Bekelman, J.E., primary, Handorf, E., additional, Guzzo, T., additional, Resnick, M., additional, Swisher-McClure, S., additional, Pollack, C., additional, Ten Have, T., additional, and Mitra, N., additional
- Published
- 2011
- Full Text
- View/download PDF
14. Brief intervention for alcohol problems in a university hospital emergency department: a randomized controlled trial
- Author
-
Haque, A., primary, Helmkamp, J., additional, Hungerford, D., additional, Williams, J., additional, Ehrlich, P., additional, Swisher-Mcclure, S., additional, Furbee, P., additional, and Manley, W., additional
- Published
- 2003
- Full Text
- View/download PDF
15. Characteristics of individuals with risk for alcohol problems in a rural university emergency department identified by AUDIT-C
- Author
-
Haque, A., primary, Helmkamp, J., additional, Swisher-Mcclure, S., additional, Williams, J., additional, Ehrlich, P., additional, Furbee, P., additional, and Manley, W., additional
- Published
- 2003
- Full Text
- View/download PDF
16. Screening and brief intervention for alcohol problems in a university student health clinic.
- Author
-
Ehrlich PF, Haque A, Swisher-McClure S, and Helmkamp J
- Abstract
The purposes of this study were (1) to determine whether a university student health center (SHC) is a feasible location to introduce a campus-based screening and brief intervention (SBI) program for alcohol and (2) to determine whether the patients seen in the SHC differ in terms of the prevalence and severity of alcohol-related problems compared with students reported by emergency department programs. The authors used motivational interview techniques to counsel subjects from a convenience sample of patients waiting for medical treatment in the SHC who had screened positive with the Alcohol Use Disorders Identification Test (AUDIT). The authors interviewed patients again after 3 months. Seventy-five percent of eligible students participated. Sixty percent screened positive and received an intervention. The authors contacted 66 students (51.2%) again after 3 months. Seventy-five percent of students interviewed again after 3 months reported that SBI was helpful, 92% found the information clear, and 90% thought that the SHC was a good place to learn this information. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
17. Esophageal cancer in a young woman with bulimia nervosa: a case report
- Author
-
Shinohara Eric T, Swisher-McClure Samuel, Husson Michael, Sun Weijing, and Metz James M
- Subjects
Medicine - Abstract
Abstract Adenocarcinoma of the esophagus has increased dramatically within the United States and continues to have a poor prognosis despite aggressive treatment. Identifying potential risk factors is critical for the early detection and treatment of this disease. The present case report describes a very young woman who developed adenocarcinoma of the esophagus after only a brief history of bulimia. These findings suggest that even in very young patients, bulimia may represent a risk factor for adenocarcinoma of the esophagus.
- Published
- 2007
- Full Text
- View/download PDF
18. External beam radiotherapy for thyroid cancer: Patients, complications, and survival.
- Author
-
Goodsell K, Ermer J, Amjad W, Swisher-McClure S, and Wachtel H
- Subjects
- Humans, Retrospective Studies, Radiotherapy, Thyroid Neoplasms radiotherapy, Thyroid Neoplasms surgery
- Abstract
Background: Patterns of utilization of external beam radiation therapy (EBRT) in thyroid cancer are incompletely described. We characterize therapeutic intent, complications, and survival in thyroid cancer treated with EBRT., Methods: In this retrospective study of 105 thyroid cancer patients treated with EBRT at one institution (2008-2018), the primary outcome was overall survival. Secondary outcomes included incomplete treatment, emergency department (ED) visits, weight change, and gastrostomy placement., Results: Dominant histopathology was differentiated (44%), anaplastic (45%) and poorly-differentiated (11%) disease. EBRT was mainly utilized for locoregional control (differentiated 87%, poorly-differentiated 75%, anaplastic 92%). Palliative EBRT was more common in poorly-differentiated disease (42%). Weight loss was greater in aggressive/advanced disease (differentiated 10 lb, poorly-differentiated 27 lb, anaplastic 18 lb). Anaplastic cancer had higher rates of gastrostomy (34%) and lowest rates of treatment completion (83%). ED encounters were common (differentiated 44%, poorly-differentiated 50%, anaplastic 45%). Gastrostomy was associated with mortality on multivariable analysis in non-anaplastic malignancy., Conclusions: EBRT was most frequently administered for locoregional control in thyroid cancer. Despite complications, the majority of patients completed EBRT therapy., Competing Interests: Declaration of competing interest The authors declare they have no conflicts of interest., (Copyright © 2023. Published by Elsevier Inc.)
- Published
- 2023
- Full Text
- View/download PDF
19. Tubarial salivary gland sparing with proton therapy.
- Author
-
Wright CM, Lee DY, Kim M, Barsky AR, Teo BK, Lukens JN, Swisher-McClure S, and Lin A
- Subjects
- Cohort Studies, Humans, Quality of Life, Radiotherapy Dosage, Radiotherapy Planning, Computer-Assisted, Radiotherapy, Intensity-Modulated adverse effects, Retrospective Studies, Carcinoma, Squamous Cell radiotherapy, Head and Neck Neoplasms radiotherapy, Proton Therapy adverse effects, Radiotherapy, Intensity-Modulated methods, Salivary Glands pathology, Salivary Glands radiation effects, Xerostomia etiology, Xerostomia prevention & control
- Abstract
The recently identified bilateral macroscopic tubarial salivary glands present a potential opportunity for further toxicity mitigation for patients receiving head and neck radiotherapy. Here, we show superior dosimetric sparing of the tubarial salivary glands with proton radiation therapy (PRT) compared to intensity-modulated radiotherapy (IMRT) for patients treated postoperatively for human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC). This was a retrospective, single institutional study of all patients treated with adjuvant PRT for HPV-associated OPSCC from 2015 to 2019. Each patient had a treatment-approved, equivalent IMRT plan to serve as a reference. The main end point was dose delivered to the tubarial salivary glands by modality, assessed via a 2-tailed, paired t-test. We also report disease outcomes for the entire cohort, via the Kaplan-Meier method. Sixty-four patients were identified. The mean RT dose to the tubarial salivary glands was 23.6 Gy (95% confidence interval (CI) 21.7 to 25.5) and 30.4 Gy (28.6 to 32.2) for PRT and IMRT plans (p < 0.0001), respectively. With a median follow-up of 25.2 months, the two-year locoregional control, progression-free survival and overall survival were 97.8% (95% CI 85.6% to 99.7%), 94.1% (82.8% to 98.1%) and 98.1% (87.4% to 99.7%), respectively. Our study suggests that meaningful normal tissue sparing of the recently identified tubarial salivary glands is achievable with PRT. The apparent gains with PRT did not impact disease outcomes, with only 1 observed locoregional recurrence (0 local, 1 regional). Further studies are warranted to explore the impact of the improved dosimetric sparing of the tubarial salivary glands conveyed by PRT on patient toxicity and quality of life., Competing Interests: Conflicts of Interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest, (Copyright © 2022 American Association of Medical Dosimetrists. Published by Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
20. Prognostic significance of conventional and volumetric PET parameters with and without partial volume correction in the assessment of head and neck squamous cell carcinoma.
- Author
-
Zirakchian Zadeh M, Asadollahi S, Kaghazchi F, Raynor WY, Mehdizadeh Seraj S, Werner TJ, Seierstad T, Korostoff J, Swisher-McClure S, Alavi A, and Revheim ME
- Subjects
- Humans, Fluorodeoxyglucose F18, Prognosis, Radiopharmaceuticals, Retrospective Studies, Squamous Cell Carcinoma of Head and Neck diagnostic imaging, Tumor Burden, Head and Neck Neoplasms diagnostic imaging, Positron Emission Tomography Computed Tomography
- Abstract
Background: The optimal quantification of PET in assessment of head and neck squamous cell carcinoma (HNSCC) is still under development. The effect of partial volume correction (PVC) on the evaluation of survival in the HNSCC patients has not been investigated yet., Methodology: Pretreatment 18F-FDG-PET/CT scans of a selected group of 57 patients with advanced stage HNSCC were collected. Conventional (SUVmean and SUVmax) and volumetric [total lesion glycolysis (TLG) and metabolic tumor volume (MTV)] PET metrics were calculated. The ROVER software (ABX GmbH, Radeberg, Germany) automatically applied PVC to the PET metrics. Cox proportional hazards regression model calculated hazard ratio (HR) for assessment of predictive parameters of progression-free survival (PFS)., Results: In multivariate Cox regression analysis, including age, gender, race, human papillomavirus status, and stage, the only significant predictors of PFS were the volumetric PET parameters (TLG: HR, 1.003; 95% CI, 1.001-1.005; P = 0.02), pvcTLG (HR, 1.002; 95% CI, 1.001-1.004; P = 0.01) and MTV (HR, 1.050; 95% CI, 1.024-1.077; P < 0.01). The partial volume-corrected values were significantly higher than the noncorrected values (Wilcoxon sign test; P < 0.05). However, there was not a statistically significant difference between the nonpartial volume corrected and partial volume-corrected PET metrics for assessment of PFS., Conclusion: Volumetric PET metrics were predictors of PFS in Cox regression analysis. Applying PVC could not significantly improve the accuracy of PET metrics for assessment of PFS., (Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
21. Sex-based differences in outcomes among surgically treated patients with HPV-related oropharyngeal squamous cell carcinoma.
- Author
-
Shinn JR, Carey RM, Mady LJ, Shimunov D, Parhar HS, Cannady SB, Rajasekaran K, Lukens JN, Lin A, Swisher-McClure S, Cohen RB, Bauml JM, Rassekh CH, Newman JG, Chalian AA, Basu D, Weinstein GS, and Brody RM
- Subjects
- Female, Humans, Male, Retrospective Studies, Sex Characteristics, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell radiotherapy, Head and Neck Neoplasms, Oropharyngeal Neoplasms pathology, Papillomavirus Infections
- Abstract
Objectives: Sex differences in surgically treated HPV-associated oropharyngeal squamous cell carcinoma are not defined due to the low number of affected women. We explored the oncologic outcomes of men and women with p16-positive oropharyngeal squamous cell carinoma treated with primary surgery., Materials and Methods: Retrospective analysis of patients with HPV-related oropharyngeal cancer treated with surgery and pathology guided adjuvant therapy from 2007 to 2017. Primary end point was recurrence-free and overall survival., Results: Of 468 men (86.7%) and 72 women (13.3%), women presented more often with clinical N0 nodal disease (25% vs 12.2%). There were no differences in adverse pathologic features or T stage, although women were more likely to present with N0 disease (16.7% vs 10%), less N2 disease (6.9% vs 17.7%, p = 0.03), and more stage I disease (88.9% vs 75%). As a result, women were more likely to undergo surgery alone (30.6% vs 14.1%) while men were more likely to require adjuvant radiation therapy (47.2% vs 36.1%). Four women (5.6%) and 30 men (6.4%, p = 0.8) died during follow-up. Multivariate analysis controlling for age, sex, treatment, and pathologic stage demonstrated no differences in overall survival between men and women. There were no differences in recurrence-free or overall survival between men and women at two and five years., Conclusions: Although women undergoing transoral robotic surgery for HPV+ oropharyngeal squamous cell carcinoma may have less advanced disease, upfront surgery with pathology-guided adjuvant therapy produces similar oncologic results in men and women while accounting for disease burden., (Copyright © 2021 Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
22. Dosimetric Results for Adjuvant Proton Radiation Therapy of HPV-Associated Oropharynx Cancer.
- Author
-
Wright CM, Baron J, Lee DY, Kim M, Barsky AR, Teo BK, Lukens JN, Swisher-McClure S, and Lin A
- Abstract
Purpose: One significant advantage of proton therapy is its ability to improve normal tissue sparing and toxicity mitigation, which is relevant in the treatment of oropharyngeal squamous cell carcinoma (OPSCC). Here, we report our institutional experience and dosimetric results with adjuvant proton radiation therapy (PRT) versus intensity-modulated radiotherapy (IMRT) for Human Papilloma Virus (HPV)-associated OPSCC., Materials and Methods: This was a retrospective, single institutional study of all patients treated with adjuvant PRT for HPV-associated OPSCC from 2015 to 2019. Each patient had a treatment-approved equivalent IMRT plan to serve as a reference. Endpoints included dosimetric outcomes to the organs at risk (OARs), local regional control (LRC), progression-free survival (PFS), and overall survival (OS). Descriptive statistics, a 2-tailed paired t test for dosimetric comparisons, and the Kaplan-Meier method for disease outcomes were used., Results: Fifty-three patients were identified. Doses delivered to OARs compared favorably for PRT versus IMRT, particularly for the pharyngeal constrictors, esophagus, larynx, oral cavity, and submandibular and parotid glands. The achieved normal tissue sparing did not negatively impact disease outcomes, with 2-year LRC, PFS, and OS of 97.0%, 90.3%, and 97.5%, respectively., Conclusion: Our study suggests that meaningful normal tissue sparing in the postoperative setting is achievable with PRT, without impacting disease outcomes., Competing Interests: Conflicts of Interest: The authors have no relevant conflicts of interest to disclose., (©Copyright 2021 The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
23. Implementation of FDG-PET/CT imaging methodology for quantification of inflammatory response in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial.
- Author
-
Jahangiri P, Dreyfuss AD, Duan F, Snyder BS, Borja AJ, Pournazari K, Kothekar E, Arani L, Al-Zaghal A, Seraj SM, Hancin EC, Pinheiro B, Werner TJ, Swisher-McClure S, Feigenberg SJ, Torigian DA, Revheim ME, Simone CB 2nd, and Alavi A
- Abstract
We measured changes in 18F-fluorodeoxyglucose (FDG) uptake on positron emission tomography/computed tomography (PET/CT) images in the lung parenchyma to quantify the degree of lung inflammation in patients with locally advanced non-small cell lung cancer (NSCLC) who received radiotherapy (RT). The goal of this study was to demonstrate successful implementation of this imaging methodology on NSCLC patients and to report quantitative statistics between pre-RT and post-RT. Seventy-one patients with NSCLC underwent FDG-PET/CT imaging before and after RT in a prospective study (ACRIN 6668/RTOG 0235). Comparisons between pre-RT and post-RT PET/CT were conducted for partial volume corrected (PVC)-mean standardized uptake value (SUVmean), PVC-global lung parenchymal glycolysis (GLPG), and lung volume for both ipsilateral and contralateral lungs using the nonparametric Wilcoxon signed-rank test. Regression modeling was conducted to associate clinical characteristics with post-RT PET/CT parameters. There was a significant increase in average SUVmean and GLPG of the ipsilateral lung (relative change 40% and 20%) between pre-RT and post-RT PET/CT scans (P<0.0001 and P=0.004). Absolute increases in PVC-SUVmean and PVC-GLPG were more pronounced (ΔPVC-SUVmean 0.32 versus ΔSUVmean 0.28; ΔPVC-GLPG 463.34 cc versus ΔGLPG 352.90 cc) and highly significant (P<0.0001). In contrast, the contralateral lung demonstrated no significant difference between pre-RT to post-RT in either GLPG (P=0.12) or SUVmean (P=0.18). The only clinical feature significantly associated with post-RT PET/CT parameters was clinical staging. Our study demonstrated inflammatory response in the ipsilateral lung of NSCLC patients treated with photon RT, suggesting that PET/CT parameters may serve as biomarkers for radiation pneumonitis (RP)., Competing Interests: None., (AJNMMI Copyright © 2021.)
- Published
- 2021
24. Definitive tumor directed therapy confers a survival advantage for metachronous oligometastatic HPV-associated oropharyngeal cancer following trans-oral robotic surgery.
- Author
-
Wright CM, Lee DY, Shimunov D, Carmona R, Barsky AR, Sun L, Cohen RB, Bauml JM, Brody RM, Basu D, Rassekh CH, Chalian AA, Newman JG, Rajasekaran K, Weinstein GS, Lukens JN, Lin A, and Swisher-McClure S
- Subjects
- Alphapapillomavirus, Humans, Prognosis, Retrospective Studies, Oropharyngeal Neoplasms surgery, Oropharyngeal Neoplasms virology, Papillomavirus Infections complications, Robotic Surgical Procedures, Squamous Cell Carcinoma of Head and Neck surgery, Squamous Cell Carcinoma of Head and Neck virology
- Abstract
Objectives: To assess the prognostic significance of oligometastatic versus polymetastatic disease in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC), and to evaluate the impact of definitive tumor directed therapy on the survival outcomes for patients with oligometastatic disease when compared to systemic therapy., Materials and Methods: This was a retrospective observational cohort study of patients with HPV-associated OPSCC who developed distant metachronous metastatic disease after undergoing initial primary surgical management from 2008 to 2017. We classified patients based on the extent of metastatic disease [Oligometastatic (≤5 metastases) and polymetastatic (>5 metastases)], and the initial treatment of metastatic disease [definitive tumor directed therapy (all metastases treated with surgery or radiotherapy) versus upfront systemic therapy]., Results: Among 676 patients undergoing primary surgical management for HPV-associated OPSCC, 39 patients (5.8%) developed metastases after a median follow-up of 29.6 months (range 4.5-127.0). Of the 34 metastatic patients who met study criteria, 26 (76.5%) were oligometastatic and 8 (23.5%) were polymetastatic. Oligometastatic patients had improved median overall survival (OS) compared to polymetastatic patients (47.9 vs. 22.7 months, p = 0.036). For oligometastatic patients, definitive tumor directed therapy was associated with an improved median progression free survival (not reached vs 6.13 months, p = 0.001) and median OS (not reached vs 40.7 months, p = 0.004)., Conclusion: In a cohort of patients surgically treated for HPV-associated OPSCC, metachronous metastatic disease was uncommon and, in most cases, considered oligometastatic. Oligometastasis portends a favorable prognosis and definitive tumor directed therapy may be associated with improved overall survival in these patients. Future multi-institutional efforts are warranted to further demonstrate the impact of definitive tumor directed therapy on disease outcomes., (Copyright © 2021 Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
25. Survival and toxicity in patients with human papilloma virus-associated oropharyngeal squamous cell cancer receiving trimodality therapy including transoral robotic surgery.
- Author
-
Sun L, Shimunov D, Tan EX, Swisher-Mcclure S, Lin A, Lukens JN, Basu D, Chalian AA, Cannady SB, Newman JG, Rajasekaran K, O'Malley BW Jr, Rassekh CH, Weinstein GS, Loevner LA, Aggarwal C, Singh A, Cohen RB, Bauml JM, and Brody RM
- Subjects
- Chemoradiotherapy, Adjuvant, Humans, Papillomaviridae, Retrospective Studies, Alphapapillomavirus, Carcinoma, Squamous Cell therapy, Head and Neck Neoplasms, Oropharyngeal Neoplasms therapy, Robotic Surgical Procedures adverse effects
- Abstract
Background: Patients with oropharyngeal cancer who undergo transoral robotic surgery (TORS) and have high-risk features generally receive adjuvant chemoradiotherapy or trimodality therapy (TMT). The notion that TMT leads to high toxicity is largely based on studies that included human papilloma virus (HPV)-negative cancers and/or nonrobotic surgery; we sought to describe outcomes in HPV-associated oropharyngeal squamous cell cancer (HPV + OPSCC) undergoing TORS-TMT., Methods: In consecutive patients with HPV + OPSCC receiving TMT at an academic center from 2010 to 2017, survival was estimated using Kaplan-Meier methodology, and toxicities were ascertained via chart review., Results: In our cohort of 178 patients, 5-year survival was 93.6%. Feeding tube rates were 25.8% at therapy completion and 0.7% at 1 year. Rates of grade ≥ 3 kidney injury, anemia, and neutropenia in cisplatin-treated patients were 2.7%, 3.4%, and 11.0%, respectively., Conclusions: Patients with HPV + OPSCC who underwent TORS-TMT had excellent survival and low rates of toxicity and feeding tube dependence. These outcomes compare favorably to historical cohorts treated with definitive chemoradiotherapy., (© 2021 Wiley Periodicals LLC.)
- Published
- 2021
- Full Text
- View/download PDF
26. Oncologic outcomes of transoral robotic surgery for HPV-negative oropharyngeal carcinomas.
- Author
-
Parhar HS, Weinstein GS, O'Malley BW Jr, Shimunov D, Rassekh CH, Chalian AA, Newman JG, Basu D, Cannady SB, Rajasekaran K, Lin A, Lukens JN, Swisher-McClure S, Cohen RB, Bauml JM, Aggrawal C, and Brody RM
- Subjects
- Chemoradiotherapy, Adjuvant, Humans, Retrospective Studies, Carcinoma, Squamous Cell surgery, Oropharyngeal Neoplasms surgery, Papillomavirus Infections, Robotic Surgical Procedures adverse effects
- Abstract
Background: Patients with human papillomavirus (HPV)-negative oropharyngeal squamous cell carcinoma (OPSCC) continue to experience disappointing outcomes following chemoradiotherapy (CRT) and appreciable morbidity following historical surgical approaches. We aimed to investigate the oncologic outcomes and perioperative morbidity of a transoral robotic surgery (TORS) approach to surgically resectable HPV-negative OPSCC., Methods: Retrospective analysis HPV-negative OPSCC patients who underwent TORS, neck dissection and pathology-guided adjuvant therapy (2005-2017)., Results: Fifty-six patients (91.1% stage III/IV) were included. Three-year overall survival, locoregional control, and disease-free survival were 85.5%, 84.4%, and 73.6%, respectively (median follow-up 30.6 months, interquartile range 18.4-66.6). Eighteen (32.1%) patients underwent adjuvant radiotherapy and 20 (39.3%) underwent adjuvant CRT. Perioperative mortality occurred in one (1.8%) patient and hemorrhage occurred in two (3.6%) patients. Long-term gastrostomy and tracheostomy rates were 5.4% and 0.0%, respectively., Conclusion: The TORS approach for resectable HPV-negative OPSCC can achieve encouraging oncologic outcomes with infrequent morbidity., (© 2021 Wiley Periodicals LLC.)
- Published
- 2021
- Full Text
- View/download PDF
27. Oncologic and survival outcomes for resectable locally-advanced HPV-related oropharyngeal cancer treated with transoral robotic surgery.
- Author
-
Yver CM, Shimunov D, Weinstein GS, Rajasekaran K, Cannady SB, Lukens JN, Lin A, Swisher-McClure S, Cohen RB, Aggarwal C, Bauml JM, Loevner LA, Newman JG, Chalian AA, Rassekh CH, Basu D, O'Malley BW Jr, and Brody RM
- Subjects
- Alphapapillomavirus, Chemoradiotherapy, Adjuvant, Humans, Neoplasm Staging, Retrospective Studies, Oropharyngeal Neoplasms pathology, Oropharyngeal Neoplasms surgery, Oropharyngeal Neoplasms virology, Papillomavirus Infections pathology, Robotic Surgical Procedures
- Abstract
Objectives: To determine whether up-front trans-oral robotic surgery (TORS) for clinically-staged locally-advanced human papillomavirus (HPV)-related oropharyngeal cancer is associated with oncologic and survival outcomes comparable to early-stage (cT1/T2) tumors., Materials and Methods: Retrospective cohort study of 628 patients with HPV-related oropharyngeal cancer who underwent up-front TORS from 2007 to 2017. Patients were stratified into two cohorts based on early-stage (cT1/2) versus locally-advanced (cT3/4) tumor at presentation., Results: We identified 589 patients who presented with early-stage tumors, and 39 patients with locally-advanced tumors. Of these, 73% of patients required adjuvant radiation, and 33% required adjuvant chemoradiation. There was no significant difference in the administration of adjuvant radiation or chemoradiation between the two cohorts. Patients in the locally-advanced disease cohort were significantly more likely to have Stage II/III disease by clinical and pathologic criteria by American Joint Committee on Cancer 8th edition criteria (p < 0.001). However, there was no significant difference in 5-year overall survival (OS) or recurrence-free survival (RFS) based on Kaplan-Meier survival estimates between the two cohorts (p = 0.75, 0.6, respectively), with estimated OS of 91% at 5 years, and estimated RFS of 86% at 5 years across the study population., Conclusions: Up-front TORS offers favorable survival outcomes for appropriately selected locally-advanced cases of HPV-related oropharyngeal cancer. Furthermore, up-front TORS is comparably effective in allowing avoidance of adjuvant therapy, particularly chemotherapy, in both cT1/T2 and locally-advanced HPV-positive oropharyngeal cancer. In the absence of clear technical contraindication to surgery, cT3/T4 classification should not be considered an absolute contraindication to surgery., (Copyright © 2021 Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
28. Disparities and guideline adherence for HPV testing among patients with oropharyngeal squamous cell carcinoma, NCDB, and SEER.
- Author
-
Husain S, Lohia S, Petkov V, Blackwell T, Swisher-McClure S, Mizrachi A, Morris LG, Cohen MA, Wong RJ, and Roman BR
- Subjects
- Guideline Adherence, Humans, Papillomaviridae, Squamous Cell Carcinoma of Head and Neck, Alphapapillomavirus, Carcinoma, Squamous Cell diagnosis, Carcinoma, Squamous Cell therapy, Head and Neck Neoplasms therapy, Oropharyngeal Neoplasms diagnosis, Oropharyngeal Neoplasms therapy, Papillomavirus Infections diagnosis, Papillomavirus Infections epidemiology
- Abstract
Background: Human papilloma virus testing for oropharyngeal squamous-cell carcinoma has been recommended by the National Comprehensive Cancer Network since 2012. We examine disparities, reported rates of human papillomavirus (HPV) testing, and the impact on these findings of limitations with the variable in database registries., Methods: The HPV variable was queried for patients with oropharyngeal squamous carcinoma (OPSCC) from 2013 to 2016 in National Cancer Data Base (NCDB) and Surveillance, Epidemiology, and End Results (SEER). Multivariable regression was used to identify disparities based on sociodemographic variables. Sensitivity analyses were used to investigate limitations of the variable., Results: Despite limitations in the HPV variable in the databases, there was less than 100% adherence to recommended testing, and there were significant disparities in multiple sociodemographic variables. For example, in NCDB 70% of white versus 60.4% of black patients were tested (odds ratio [OR] 0.75, confidence interval [CI] 0.66-0.85, p ≤ 0.0001); in SEER 59.8% of white and 47.6% of black patients were tested (OR 0.73, CI 0.67-0.81; p ≤ 0.0001)., Conclusions: Disparities exist among patients undergoing testing for HPV-associated OPSCC and adherence to guideline recommended HPV testing has been suboptimal. In addition, the HPV variable definition, especially as it relates to p16 positivity, and use in these two registries should be improved., (© 2021 Wiley Periodicals LLC.)
- Published
- 2021
- Full Text
- View/download PDF
29. Dual-Energy Computed Tomography Proton-Dose Calculation with Scripting and Modified Hounsfield Units.
- Author
-
Kassaee A, Cheng C, Yin L, Zou W, Li T, Lin A, Swisher-McClure S, Lukens JN, Lustig RA, O'Reilly S, Dong L, Ms RH, and Teo BK
- Abstract
Purpose: To describe an implementation of dual-energy computed tomography (DECT) for calculation of proton stopping-power ratios (SPRs) in a commercial treatment-planning system. The process for validation and the workflow for safe deployment of DECT is described, using single-energy computed tomography (SECT) as a safety check for DECT dose calculation., Materials and Methods: The DECT images were acquired at 80 kVp and 140 kVp and were processed with computed tomography scanner software to derive the electron density and effective atomic number images. Reference SPRs of tissue-equivalent plugs from Gammex (Middleton, Wisconsin) and CIRS (Computerized Imaging Reference Systems, Norfolk, Virginia) electron density phantoms were used for validation and comparison of SECT versus DECT calculated through the Eclipse treatment planning system (Varian Medical Systems, Palo Alto, California) application programming interface scripting tool. An in-house software was also used to create DECT SPR computed tomography images for comparison with the script output. In the workflow, using the Eclipse system application programming interface script, clinical plans were optimized with the SECT image set and then forward-calculated with the DECT SPR for the final dose distribution. In a second workflow, the plans were optimized using DECT SPR with reduced range-uncertainty margins., Results: For the Gammex phantom, the root mean square error in SPR was 1.08% for DECT versus 2.29% for SECT for 10 tissue-surrogates, excluding the lung. For the CIRS Phantom, the corresponding results were 0.74% and 2.27%. When evaluating the head and neck plan, DECT optimization with 2% range-uncertainty margins achieved a small reduction in organ-at-risk doses compared with that of SECT plans with 3.5% range-uncertainty margins. For the liver case, DECT was used to identify and correct the lipiodol SPR in the SECT plan., Conclusion: It is feasible to use DECT for proton-dose calculation in a commercial treatment planning system in a safe manner. The range margins can be reduced to 2% in some sites, including the head and neck., Competing Interests: Conflicts of Interest: Lei Dong, PhD, is an Associate Editor of the International Journal of Particle Therapy. This work was partially funded by Varian Medical Systems. The authors have no additional conflicts of interest to disclose., (©Copyright 2021 The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
30. Increased rate of recurrence and high rate of salvage in patients with human papillomavirus-associated oropharyngeal squamous cell carcinoma with adverse features treated with primary surgery without recommended adjuvant therapy.
- Author
-
Carey RM, Shimunov D, Weinstein GS, Cannady SB, Lukens JN, Lin A, Swisher-McClure S, Bauml JM, Aggarwal C, Cohen RB, Newman JG, Chalian AA, Rassekh CH, Basu D, O'Malley BW Jr, Rajasekaran K, and Brody RM
- Subjects
- Humans, Neoplasm Recurrence, Local, Papillomaviridae, Retrospective Studies, Squamous Cell Carcinoma of Head and Neck surgery, Alphapapillomavirus, Carcinoma, Squamous Cell therapy, Head and Neck Neoplasms, Oropharyngeal Neoplasms surgery, Robotic Surgical Procedures adverse effects
- Abstract
Background: Some patients with human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) do not receive guideline-recommended postoperative radiation therapy (PORT) following primary transoral robotic surgery (TORS)., Methods: Three-hundred and sixty-four patients with treatment-naïve, HPV-associated OPSCC were recommended to receive PORT based on clinicopathological features following TORS. Patients were stratified based on if they received PORT. Oncologic outcomes were compared., Results: The 3-year locoregional failure (LRF) was 32% in patients who did not receive PORT and 4% in patients who received PORT (P < .001). Despite increased LRF, avoiding PORT was not associated with increased 3-year distant metastasis rates (8% vs 4%, P = .56) or worse 3-year survival (95% vs 98%, P = .34). Recurrences in the surgery alone cohort varied between local and regional sites and were often successfully salvaged., Conclusions: Patients with HPV-associated OPSCC who do not receive indicated PORT have an increased risk of LRF but similar survival due to high salvage rates., (© 2020 Wiley Periodicals LLC.)
- Published
- 2021
- Full Text
- View/download PDF
31. Early Changes in Physical Activity and Quality of Life With Thoracic Radiation Therapy in Breast Cancer, Lung Cancer, and Lymphoma.
- Author
-
Krishnan S, Narayan HK, Freedman G, Plastaras JP, Maity A, Demissei B, Smith AM, Berman AT, Cengel K, Levin W, Swisher-McClure S, Feigenberg S, and Ky B
- Subjects
- Adult, Aged, Breast Neoplasms psychology, Female, Humans, Longitudinal Studies, Lung Neoplasms psychology, Lymphoma psychology, Male, Mediastinal Neoplasms psychology, Middle Aged, Prospective Studies, Breast Neoplasms radiotherapy, Exercise, Lung Neoplasms radiotherapy, Lymphoma radiotherapy, Mediastinal Neoplasms radiotherapy, Quality of Life, Thorax radiation effects
- Abstract
Purpose: The effects of thoracic radiation therapy (RT) on physical functioning and quality of life (QoL) are incompletely defined. We determined the associations between thoracic RT dose volume metrics, physical activity, and QoL in patients with cancer., Methods and Materials: Participants with breast cancer, lung cancer, or mediastinal lymphoma treated with radiation with or without chemotherapy were enrolled in a prospective, longitudinal cohort study. Data were collected pre-RT, immediately post-RT, and 5 to 9 months post-RT. At each timepoint, self-reported physical activity was assessed via the Godin-Shephard Leisure-Time Physical Activity Questionnaire, and QoL metrics were assessed via Functional Assessment of Chronic Illness Therapy Fatigue and Dyspnea Scales. Multivariable adjusted linear regression models were stratified by breast cancer alone and lung cancer and lymphoma combined., Results: One hundred thirty participants were included in the study. In breast cancer (n = 80), each 1-Gy increase in mean heart dose was associated with worse Functional Assessment of Chronic Illness Therapy Fatigue scores (-1.0; 95% confidence interval [CI], -1.9 to -0.2; P = .021); similar associations were observed between V5 and fatigue (-2.5; 95% CI, -4.4 to -0.6; P = .010 for each 10% increase in V5). In lung cancer and lymphoma (n = 50), each 10% increase in V5 was associated with decreased physical activity (Godin-Shephard Leisure-Time Physical Activity Questionnaire score -2.3; 95% CI, -4.3 to -0.4; P = .017). Although the associations between baseline levels of physical activity and fatigue and dyspnea were of borderline significance in breast cancer alone (P < .10), increased physical activity over time was associated with improvements in fatigue and dyspnea across all cancer types (P < .05 for all)., Conclusions: Higher cardiac RT dose was associated with worse fatigue and physical activity across breast cancer, lung cancer, and mediastinal lymphoma. Longitudinal increases in physical activity were associated with concurrent improvements in QoL measures. Strategies to increase physical activity and decrease cardiac RT dose may improve physical functioning and QoL for patients with cancer., (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
32. Association of Antibiotic Exposure With Survival and Toxicity in Patients With Melanoma Receiving Immunotherapy.
- Author
-
Mohiuddin JJ, Chu B, Facciabene A, Poirier K, Wang X, Doucette A, Zheng C, Xu W, Anstadt EJ, Amaravadi RK, Karakousis GC, Mitchell TC, Huang AC, Shabason JE, Lin A, Swisher-McClure S, Maity A, Schuchter LM, and Lukens JN
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Anti-Bacterial Agents therapeutic use, Antineoplastic Agents, Immunological administration & dosage, Antineoplastic Agents, Immunological adverse effects, Disease-Free Survival, Female, Gastrointestinal Microbiome drug effects, Genetic Variation genetics, Humans, Immune Checkpoint Inhibitors administration & dosage, Immune Checkpoint Inhibitors adverse effects, Immunologic Factors antagonists & inhibitors, Immunologic Factors genetics, Immunotherapy adverse effects, Male, Melanoma microbiology, Melanoma mortality, Melanoma pathology, Middle Aged, Neoplasm Staging, Young Adult, Anti-Bacterial Agents adverse effects, Gastrointestinal Microbiome genetics, Genetic Variation drug effects, Melanoma drug therapy
- Abstract
Background: Gut microbial diversity is associated with improved response to immune checkpoint inhibitors (ICI). Based on the known detrimental impact that antibiotics have on microbiome diversity, we hypothesized that antibiotic receipt prior to ICI would be associated with decreased survival., Methods: Patients with stage III and IV melanoma treated with ICI between 2008 and 2019 were selected from an institutional database. A window of antibiotic receipt within 3 months prior to the first infusion of ICI was prespecified. The primary outcome was overall survival (OS), and secondary outcomes were melanoma-specific mortality and immune-mediated colitis requiring intravenous steroids. All statistical tests were two-sided., Results: There were 568 patients in our database of which 114 received antibiotics prior to ICI. Of the patients, 35.9% had stage III disease. On multivariable Cox proportional hazards analysis of patients with stage IV disease, the antibiotic-exposed group had statistically significantly worse OS (hazard ratio [HR] = 1.81, 95% confidence interval [CI] = 1.27 to 2.57; P <.001). The same effect was observed among antibiotic-exposed patients with stage III disease (HR = 2.78, 95% CI = 1.31 to 5.87; P =.007). When limited to only patients who received adjuvant ICI (n = 89), antibiotic-exposed patients also had statistically significantly worse OS (HR = 4.84, 95% CI = 1.09 to 21.50; P =.04). The antibiotic group had a greater incidence of colitis (HR = 2.14, 95% CI = 1.02 to 4.52; P =.046)., Conclusion: Patients with stage III and IV melanoma exposed to antibiotics prior to ICI had statistically significantly worse OS than unexposed patients. Antibiotic exposure was associated with greater incidence of moderate to severe immune-mediated colitis. Given the large number of antibiotics prescribed annually, physicians should be judicious with their use in cancer populations likely to receive ICI., (© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
33. Photobiomodulation Therapy in Head and Neck Cancer-Related Lymphedema: A Pilot Feasibility Study.
- Author
-
Deng J, Lukens JN, Swisher-McClure S, Cohn JC, Spinelli BA, Quinn RJ, Chittams J, McMenamin E, and Lin A
- Subjects
- Feasibility Studies, Humans, Quality of Life, Head and Neck Neoplasms radiotherapy, Low-Level Light Therapy, Lymphedema etiology, Lymphedema therapy
- Abstract
Purpose: Lymphedema is a common debilitating late effect among patients post-head and neck cancer (HNC) treatment. Head and neck lymphedema was associated with symptom burden, functional impairment, and decreased quality of life. The objective of this study was to determine the feasibility and potential efficacy of the use of photobiomodulation (PBM) therapy for head and neck lymphedema, symptom burden, and neck range of motion among HNC survivors., Methods: This was a single-arm, pre- and post-design clinical trial. Eligible patients included those with lymphedema after completion of complete decongestive therapy (CDT) and 3 to 18 months after completion of cancer therapy. The intervention included PBM therapy 2 times a week for 6 weeks for a total of 12 treatments. Lymphedema, symptom burden, and neck range of motion were measured at baseline, end-of-intervention, and 4-week post-intervention., Results: Of the 12 patients enrolled in the study, 91.7% (n = 11) completed the study intervention and assessment visits, and no adverse events were reported. When comparing the baseline to 4-week post-intervention, we found statistically significant improvements in the severity of external lymphedema, symptom burden, and neck range of motion (all P < .05)., Conclusion: PBM therapy was feasible and potentially effective for the treatment of head and neck lymphedema. Future randomized controlled trials are warranted to examine the efficacy of PBM therapy for HNC-related lymphedema., Trial Registration Number and Date of Registration: ClinicalTrials.gov Identifier: NCT03738332; date of registration: November 13, 2018.
- Published
- 2021
- Full Text
- View/download PDF
34. 18 F-FDG-PET/CT in radiation therapy-induced parotid gland inflammation.
- Author
-
Mouminah A, Borja AJ, Hancin EC, Chang YC, Werner TJ, Swisher-McClure S, Korostoff J, Alavi A, and Revheim ME
- Abstract
Background:
18 F-fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) is used in the clinical management of oncologic and inflammatory pathologies. It may have utility in detecting radiotherapy (RT)-induced damage of oral tissues. Thus, the aim of the present study was to use FDG-PET/CT to evaluate parotid gland inflammation following RT in patients with head and neck cancer (HNC)., Methods: This retrospective study included patients with HNC treated with photon, proton, or combined photon/proton RT, in addition to chemotherapy. All patients received FDG-PET/CT imaging pre-treatment and 3 months post-treatment. The average mean standardized uptake value (Avg SUVmean) and the average maximum standardized uptake value (Avg SUVmax) of the left and right parotid glands were determined by global assessment of FDG activity using OsiriX MD software. A two-tailed paired t test was used to compare Avg SUVmean and Avg SUVmax pre- and post-RT., Results: Forty-seven HNC patients were included in the study. Parotid gland Avg SUVmean was significantly higher at 3 months post-treatment than pre-treatment (p < 0.05) in patients treated with photon RT, but no significant differences were found between pre- and post-treatment Avg SUVmean in patients treated with proton RT or combined photon/proton RT., Conclusion: Our results suggest that photon RT may cause radiation-induced inflammation of the parotid gland, and that proton RT, which distributes less off-target radiation, is a safer treatment alternative.- Published
- 2020
- Full Text
- View/download PDF
35. Oncologic Outcomes Following Transoral Robotic Surgery for Human Papillomavirus-Associated Oropharyngeal Carcinoma in Older Patients.
- Author
-
Parhar HS, Shimunov D, Newman JG, Cannady SB, Rajasekaran K, O' Malley BW Jr, Chalian AA, Rassekh CH, Cohen RB, Lin A, Lukens J, Swisher-McClure S, Bauml J, Aggarwal C, Weinstein GS, and Brody RM
- Subjects
- Age Factors, Aged, Aged, 80 and over, Carcinoma, Squamous Cell mortality, Disease-Free Survival, Female, Humans, Male, Neck Dissection, Oropharyngeal Neoplasms mortality, Papillomavirus Infections mortality, Papillomavirus Infections therapy, Retrospective Studies, Survival Rate, Treatment Outcome, Carcinoma, Squamous Cell surgery, Carcinoma, Squamous Cell virology, Oropharyngeal Neoplasms surgery, Oropharyngeal Neoplasms virology, Papillomavirus Infections complications, Robotic Surgical Procedures
- Abstract
Importance: While early epidemiologic studies ascribed increases in the incidence of human papillomavirus-associated oropharyngeal cancers to middle-aged patients, recent analyses have demonstrated an increasing median age of diagnosis. Treatment of patients older than 70 years is controversial as their inclusion in the practice-defining clinical trials has been limited and the survival benefit conferred by chemotherapy may be outweighed by treatment toxic effects., Objective: To assess the oncologic outcomes of older adults with human papillomavirus-associated oropharyngeal cancer who underwent upfront transoral robotic surgery and pathologic characteristics-guided adjuvant therapy in a large cohort of patients with close follow-up., Design, Setting, and Participants: A retrospective cohort analysis was conducted in a tertiary care academic medical center between January 1, 2010, and December 30, 2017. Patients aged 70 years or older at time of diagnosis with biopsy-proven and surgically resectable p16-positive oropharyngeal cancers were included. Data analysis was conducted from March 1 to June 1, 2020., Exposures: Transoral robotic surgery oropharyngeal resection and neck dissection with pathologic characteristic-guided adjuvant therapy., Main Outcomes and Measures: Three-year estimates of disease-specific survival, overall survival, and disease-free survival, as well as rates of adjuvant therapy (radiotherapy and chemoradiotherapy) and perioperative complications., Results: Seventy-seven patients were included (median age, 73.0; interquartile range, 71.0-76.0; range, 70-89 years); of these, 58 were men (75.3%). Perioperative mortality was 1.3% and the rate of oropharyngeal hemorrhage was 2.6%. Twenty-seven patients (35.1%) underwent postoperative radiotherapy and 20 patients (26.0%) underwent postoperative chemoradiotherapy. The median length of follow-up was 39.6 (range, 0.1-96.2) months, and the 3-year estimates of survival were 92.4% (95% CI, 82.4%-96.9%) for disease-specific survival, 90.0% (95% CI, 79.4%-95.0%) for overall survival, and 84.3% (95% CI, 73.4%-91.0%) for disease-free survival., Conclusions and Relevance: The findings of this cohort study suggest that transoral robotic surgery and pathologic characteristic-guided adjuvant therapy can provide beneficial survival outcomes, infrequent perioperative mortality, and, for most carefully selected older adults, obviate the need for chemotherapy.
- Published
- 2020
- Full Text
- View/download PDF
36. Radiation Oncology Rotation in Botswana: Resident Experience and Career Interests.
- Author
-
Mante A, Hawrot K, Bvochora-Nsingo M, Chiyapo S, Balang D, Barg F, Baffic C, Monare B, Vapiwala N, Ralefala T, Metz J, Swisher-McClure S, and Grover S
- Subjects
- Adult, Botswana, Female, Humans, Male, Surveys and Questionnaires, Career Choice, Internship and Residency statistics & numerical data, Radiation Oncology education
- Published
- 2020
- Full Text
- View/download PDF
37. Penn Medicine Head and Neck Cancer Service Line COVID-19 management guidelines.
- Author
-
Weinstein GS, Cohen R, Lin A, O'Malley BW Jr, Lukens J, Swisher-McClure S, Shanti RM, Newman JG, Parhar HS, Tasche K, Brody RM, Chalian A, Cannady S, Palmer JN, Adappa ND, Kohanski MA, Bauml J, Aggarwal C, Montone K, Livolsi V, Baloch ZW, Jalaly JB, Cooper K, Rajasekaran K, Loevner L, and Rassekh C
- Subjects
- Ambulatory Care standards, COVID-19, Combined Modality Therapy, Continuity of Patient Care standards, Coronavirus Infections diagnosis, Head and Neck Neoplasms diagnosis, Humans, Multi-Institutional Systems, Otorhinolaryngologic Surgical Procedures standards, Palliative Care standards, Patient Safety, Pennsylvania, Personal Protective Equipment, Pneumonia, Viral diagnosis, SARS-CoV-2, Terminal Care standards, Tertiary Care Centers, Betacoronavirus, Coronavirus Infections prevention & control, Head and Neck Neoplasms therapy, Infection Control standards, Medical Oncology standards, Pandemics prevention & control, Pneumonia, Viral prevention & control
- Abstract
Introduction: The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus has altered the health care environment for the management of head and neck cancers. The purpose of these guidelines is to provide direction during the pandemic for rational Head and Neck Cancer management in order to achieve a medically and ethically appropriate balance of risks and benefits., Methods: Creation of consensus document., Results: The process yielded a consensus statement among a wide range of practitioners involved in the management of patients with head and neck cancer in a multihospital tertiary care health system., Conclusions: These guidelines support an ethical approach for the management of head and neck cancers during the COVID-19 epidemic consistent with both the local standard of care as well as the head and neck oncological literature., (© 2020 Wiley Periodicals, Inc.)
- Published
- 2020
- Full Text
- View/download PDF
38. Circulating Tumor Cells Are Associated with Recurrent Disease in Patients with Early-Stage Non-Small Cell Lung Cancer Treated with Stereotactic Body Radiotherapy.
- Author
-
Frick MA, Feigenberg SJ, Jean-Baptiste SR, Aguarin LA, Mendes A, Chinniah C, Swisher-McClure S, Berman A, Levin W, Cengel KA, Hahn SM, Dorsey JF, Simone CB 2nd, and Kao GD
- Subjects
- Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung blood, Carcinoma, Non-Small-Cell Lung surgery, Disease Progression, Female, Humans, Lung Neoplasms blood, Lung Neoplasms surgery, Male, Neoplasm Recurrence, Local blood, Neoplasm Recurrence, Local surgery, Neoplasm Staging, Retrospective Studies, Survival Rate, Telomerase blood, Treatment Outcome, Carcinoma, Non-Small-Cell Lung pathology, Carcinoma, Non-Small-Cell Lung radiotherapy, Lung Neoplasms pathology, Lung Neoplasms radiotherapy, Neoplasm Recurrence, Local pathology, Neoplastic Cells, Circulating pathology, Radiosurgery methods
- Abstract
Purpose: Although stereotactic body radiotherapy (SBRT) is effective in early-stage non-small cell lung cancer (NSCLC), approximately 10%-15% of patients will fail regionally and 20%-25% distantly. We evaluate a novel circulating tumor cell (CTC) assay as a prognostic marker for increased risk of recurrence following SBRT., Experimental Design: Ninety-two subjects (median age, 71 years) with T1a (64%), T1b (23%), or T2a (13%) stage I NSCLC treated with SBRT were prospectively enrolled. CTCs were enumerated by utilizing a GFP-expressing adenoviral probe that detects elevated telomerase activity in cancer cells. Samples were obtained before, during, and serially up to 24 months after treatment. SBRT was delivered to a median dose of 50 Gy (range, 40-60 Gy), mostly commonly in four to five fractions (92%)., Results: Thirty-eight of 92 subjects (41%) had a positive CTC test prior to SBRT. A cutoff of ≥5 CTCs/mL before treatment defined favorable ( n = 78) and unfavorable ( n = 14) prognostic groups. Increased risk of nodal ( P = 0.04) and distant ( P = 0.03) failure was observed in the unfavorable group. Within 3 months following SBRT, CTCs continued to be detected in 10 of 35 (29%) subjects. Persistent detection of CTCs was associated with increased risk of distant failure ( P = 0.04) and trended toward increased regional ( P = 0.08) and local failure ( P = 0.16)., Conclusions: Higher pretreatment CTCs and persistence of CTCs posttreatment is significantly associated with increased risk of recurrence outside the targeted treatment site. This suggests that CTC analysis may potentially identify patients at higher risk for regional or distant recurrences and who may benefit from either systemic therapy and/or timely locoregional salvage treatment., (©2020 American Association for Cancer Research.)
- Published
- 2020
- Full Text
- View/download PDF
39. A Phase 2 Trial of Alternative Volumes of Oropharyngeal Irradiation for De-intensification (AVOID): Omission of the Resected Primary Tumor Bed After Transoral Robotic Surgery for Human Papilloma Virus-Related Squamous Cell Carcinoma of the Oropharynx.
- Author
-
Swisher-McClure S, Lukens JN, Aggarwal C, Ahn P, Basu D, Bauml JM, Brody R, Chalian A, Cohen RB, Fotouhi-Ghiam A, Geiger G, Gershowitz J, Livolsi V, Mitra N, Montone K, Newman J, Ojerholm E, O'Malley B Jr, Rajasekaran K, Tan E, Weinstein G, and Lin A
- Subjects
- Adult, Aged, Aged, 80 and over, Carcinoma, Squamous Cell pathology, Female, Humans, Male, Middle Aged, Oropharyngeal Neoplasms pathology, Treatment Outcome, Carcinoma, Squamous Cell surgery, Carcinoma, Squamous Cell virology, Oropharyngeal Neoplasms surgery, Oropharyngeal Neoplasms virology, Papillomaviridae physiology, Robotic Surgical Procedures adverse effects
- Abstract
Purpose: This trial tested the safety and efficacy of a novel, deintensified radiation therapy (RT) approach after initial surgical resection for patients with human papilloma virus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC)., Methods and Materials: This single-arm phase 2 prospective clinical trial enrolled 60 patients with stage pT1-pT2 N1-3 HPV-associated OPSCC treated with transoral robotic surgery (TORS) and selective neck dissection at a single institution between May 2014 and September 2017. Patients had favorable features at the primary site (negative surgical margins ≥2 mm, no perineural invasion, and no lymphovascular invasion) but required adjuvant therapy based on lymph node involvement. Surgeries were all performed at a high-volume head and neck cancer center with expertise in TORS. Patients received postoperative RT to at-risk areas in the involved neck (60-66 Gy) and uninvolved neck (54 Gy). The resected primary site was treated as an active avoidance structure in the treatment planning of postoperative RT. Concurrent chemotherapy was administered for patients with extranodal extension., Results: Median follow-up of the 60 patients enrolled was 2.4 years (range, 8.5-53.8 months). A single patient recurred at the primary site, for 2-year local control of 98.3%. One patient (1.7%) developed a regional neck recurrence, and 2 patients (3.3%) developed distant metastases. Measured 2-year local recurrence-free survival was 97.9% (95% confidence interval, 86.1%-99.7%). Overall survival was 100% at the time of analysis. The mean radiation dose to the primary site was 36.9 Gy (standard deviation, 10.3 Gy). Two patients (3.3%) experienced late soft tissue necrosis in the primary site surgical bed that resolved within 2 months. Feeding tube dependence rates were 0% during RT, 3.3% temporarily during follow-up, and 0% at last follow-up., Conclusions: Deintensified postoperative RT that avoids the resected primary tumor site and targets only the at-risk neck after TORS for selected patients with HPV-associated OPSCC may be safe and is worthy of further study., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
40. Inter-fraction robustness of intensity-modulated proton therapy in the post-operative treatment of oropharyngeal and oral cavity squamous cell carcinomas.
- Author
-
Hague C, Aznar M, Dong L, Fotouhi-Ghiam A, Lee LW, Li T, Lin A, Lowe M, Lukens JN, McPartlin A, O'Reilly S, Slevin N, Swisher-Mcclure S, Thomson D, Van Herk M, West C, Zou W, and Teo BK
- Subjects
- Aged, Carcinoma, Squamous Cell diagnostic imaging, Dose Fractionation, Radiation, Female, Humans, Male, Middle Aged, Mouth Neoplasms diagnostic imaging, Organs at Risk radiation effects, Oropharyngeal Neoplasms diagnostic imaging, Pilot Projects, Postoperative Care, Retrospective Studies, Spinal Cord radiation effects, Uncertainty, Carcinoma, Squamous Cell radiotherapy, Mouth Neoplasms radiotherapy, Oropharyngeal Neoplasms radiotherapy, Proton Therapy methods, Radiotherapy Planning, Computer-Assisted, Radiotherapy, Intensity-Modulated methods
- Abstract
Objective: To evaluate dosimetric consequences of inter-fraction setup variation and anatomical changes in patients receiving multifield optimised (MFO) intensity modulated proton therapy for post-operative oropharyngeal (OPC) and oral cavity (OCC) cancers., Methods: Six patients receiving MFO for post-operative OPC and OCC were evaluated. Plans were robustly optimised to clinical target volumes (CTVs) using 3 mm setup and 3.5% range uncertainty. Weekly online cone beam CT (CBCT) were performed. Planning CT was deformed to the CBCT to create virtual CTs (vCTs) on which the planned dose was recalculated. vCT plan robustness was evaluated using a setup uncertainty of 1.5 mm and range uncertainty of 3.5%. Target coverage, D
95% , and hotspots, D0.03cc , were evaluated for each uncertainty along with the vCT-calculated nominal plan. Mean dose to organs at risk (OARs) for the vCT-calculated nominal plan and relative % change in weight from baseline were evaluated., Results: Robustly optimised plans in post-operative OPC and OCC patients are robust against inter-fraction setup variations and range uncertainty. D0.03cc in the vCT-calculated nominal plans were clinically acceptable across all plans. Across all patients D95% in the vCT-calculated nominal treatment plan was at least 100% of the prescribed dose. No patients lost ≥10% weight from baseline. Mean dose to the OARs and max dose to the spinal cord remained within tolerance., Conclusion: MFO plans in post-operative OPC and OCC patients are robust to inter-fraction uncertainties in setup and range when evaluated over multiple CT scans without compromising OAR mean dose., Advances in Knowledge: This is the first paper to evaluate inter-fraction MFO plan robustness in post-operative head and neck treatment.- Published
- 2020
- Full Text
- View/download PDF
41. Pharyngeal-sparing radiation for head and neck carcinoma of unknown primary following TORS assisted work-up.
- Author
-
Grewal AS, Rajasekaran K, Cannady SB, Chalian AA, Ghiam AF, Lin A, LiVolsi V, Lukens JN, Mitra N, Montone KT, Newman JG, O'Malley BW Jr.,, Rassekh CH, Weinstein GS, and Swisher-McClure S
- Subjects
- Carcinoma secondary, Carcinoma surgery, Case-Control Studies, Female, Head and Neck Neoplasms secondary, Head and Neck Neoplasms surgery, Humans, Male, Middle Aged, Neck pathology, Neck radiation effects, Neoplasms, Unknown Primary pathology, Neoplasms, Unknown Primary surgery, Organs at Risk pathology, Organs at Risk radiation effects, Pharyngeal Diseases etiology, Pharynx pathology, Pharynx radiation effects, Postoperative Period, Radiation Injuries etiology, Retrospective Studies, Robotic Surgical Procedures methods, Treatment Outcome, Carcinoma radiotherapy, Head and Neck Neoplasms radiotherapy, Neoplasms, Unknown Primary radiotherapy, Organ Sparing Treatments methods, Pharyngeal Diseases prevention & control, Radiation Injuries prevention & control
- Abstract
Objective: In patients with head and neck carcinoma of unknown primary (HNCUP;pT0) following TORS-assisted workup, we have adopted a pharyngeal-sparing radiation therapy (PSRT) approach targeting only the at-risk neck and omitting treatment of the pharynx. We report outcomes following PSRT, and compare to institutional historical control subjects who received pharyngeal-targeted RT (PRT)., Methods: Between 2009 and 2018, 172 patients underwent TORS-assisted endoscopy as part of their workup for HNCUP. Following TORS, 54 patients had pT0 disease, of which 45 received RT. Forty-nine percent received PSRT and 51% received PRT., Results: No statistically significant differences existed between the PSRT and PRT groups with respect to overall nodal distribution, p16 positivity (55% vs. 43%, P = .12), neck dissection rates (77% vs. 65%, P = .51), and administration of chemotherapy (55% vs. 65%, P = .55). Median follow-up for PSRT and PRT groups were 24 and 28 months, respectively (P = .04). Two-year RFS was 86% and 74% for PSRT and PRT patients, respectively (log-rank P = .30). Three and six patients recurred after PSRT and PRT, respectively. Two-year OS for PSRT and PRT patients was 91% and 74%, respectively (log-rank P = .31). Compared to PRT, PSRT was associated with statistically significantly less: grade 2+ mucositis (18% vs. 91%, P < .01), new opioid requirement (27% vs. 91%, P < .01), mean weight loss during RT (6.2 lbs vs. 17.4 lbs, P < .01), feeding tube placement during RT (5% vs. 43%, P < .01), and treatment-related unplanned hospitalizations (9% vs. 39%, P = .04)., Conclusion: Following TORS-assisted management of patients with pT0 HNCUP, we observed reduced toxicity following PSRT compared to PRT without apparent compromise of disease cure., Level of Evidence: Level 3 evidence, retrospective review comparing cases and controls Laryngoscope, 130:691-697, 2020., (© 2019 The American Laryngological, Rhinological and Otological Society, Inc.)
- Published
- 2020
- Full Text
- View/download PDF
42. 18 F-FDG-PET/CT in the quantification of photon radiation therapy-induced vasculitis.
- Author
-
Borja AJ, Hancin EC, Dreyfuss AD, Zhang V, Mathew T, Rojulpote C, Werner TJ, Patil S, Gonuguntla K, Lin A, Feigenberg SJ, Swisher-McClure S, Alavi A, and Revheim ME
- Abstract
Radiation therapy (RT) is an important component of care for head and neck cancers (HNC). Photon RT vasculitis is a complication of incidental dose delivery to nearby vascular structures. However, optimal methods for early diagnosis are not clearly established. The aim of this study was to evaluate
18 F-FDG-PET/CT in detecting radiation-induced vasculitis of the left common carotid (LCC) and the arch of the aorta (AoA) in patients treated for HNC.18 F-FDG-PET/CT scans obtained before RT (Pre-RT) and 3 months after RT (Post-RT) were retrospectively reviewed in 30 HNC patients (25 males, 5 females; average age 57.9±8.1 years) treated with photon RT. All subjects underwent18 F-FDG-PET/CT imaging 60 minutes after 5.0 MBq/kg18 F-FDG injection. Average standard uptake values (Avg SUVmean) of the LCC and AoA were obtained by global assessment. A two-tailed paired t-test was used to assess the difference in Avg SUVmean between pre- and post-RT imaging. Subjects demonstrated significant increased Avg SUVmean within the LCC post-RT (pre = 1.42, post = 1.65, P<0.001), with a mean increase of 0.23 SUV. Similarly, subjects exhibited higher18 F-FDG uptake in the AoA post-RT (pre = 1.44, post = 1.69, P<0.01), with a mean increase of 0.23 SUV.18 F-FDG-PET/CT may be used to detect and quantify photon RT vasculitis in HNC patients. Further investigation is warranted to evaluate the clinical implications of this pathology and the role for alternative treatment strategies in minimizing tissue toxicity., Competing Interests: None., (AJNMMI Copyright © 2020.)- Published
- 2020
43. Design, Implementation, and in Vivo Validation of a Novel Proton FLASH Radiation Therapy System.
- Author
-
Diffenderfer ES, Verginadis II, Kim MM, Shoniyozov K, Velalopoulou A, Goia D, Putt M, Hagan S, Avery S, Teo K, Zou W, Lin A, Swisher-McClure S, Koch C, Kennedy AR, Minn A, Maity A, Busch TM, Dong L, Koumenis C, Metz J, and Cengel KA
- Subjects
- Abdomen radiation effects, Animals, Cell Proliferation radiation effects, Equipment Design methods, Feasibility Studies, Female, Fibrosis, Gamma Rays, Intestine, Small pathology, Intestine, Small radiation effects, Mice, Mice, Inbred C57BL, Organ Sparing Treatments instrumentation, Organ Sparing Treatments methods, Organs at Risk pathology, Pancreatic Neoplasms radiotherapy, Proton Therapy methods, Radiation Protection methods, Radiometry methods, Radiotherapy, Image-Guided methods, Scattering, Radiation, Stem Cells radiation effects, Tomography, X-Ray Computed, Organs at Risk radiation effects, Proton Therapy instrumentation, Radiation Injuries, Experimental prevention & control, Radiation Protection instrumentation, Radiotherapy, Image-Guided instrumentation
- Abstract
Purpose: Recent studies suggest that ultrahigh-dose-rate, "FLASH," electron radiation therapy (RT) decreases normal tissue damage while maintaining tumor response compared with conventional dose rate RT. Here, we describe a novel RT apparatus that delivers FLASH proton RT (PRT) using double scattered protons with computed tomography guidance and provide the first report of proton FLASH RT-mediated normal tissue radioprotection., Methods and Materials: Absolute dose was measured at multiple depths in solid water and validated against an absolute integral charge measurement using a Faraday cup. Real-time dose rate was obtained using a NaI detector to measure prompt gamma rays. The effect of FLASH versus standard dose rate PRT on tumors and normal tissues was measured using pancreatic flank tumors (MH641905) derived from the KPC autochthonous PanCa model in syngeneic C57BL/6J mice with analysis of fibrosis and stem cell repopulation in small intestine after abdominal irradiation., Results: The double scattering and collimation apparatus was dosimetrically validated with dose rates of 78 ± 9 Gy per second and 0.9 ± 0.08 Gy per second for the FLASH and standard PRT. Whole abdominal FLASH PRT at 15 Gy significantly reduced the loss of proliferating cells in intestinal crypts compared with standard PRT. Studies with local intestinal irradiation at 18 Gy revealed a reduction to near baseline levels of intestinal fibrosis for FLASH-PRT compared with standard PRT. Despite this difference, FLASH-PRT did not demonstrate tumor radioprotection in MH641905 pancreatic cancer flank tumors after 12 or 18 Gy irradiation., Conclusions: We have designed and dosimetrically validated a FLASH-PRT system with accurate control of beam flux on a millisecond time scale and online monitoring of the integral and dose delivery time structure. Using this system, we found that FLASH-PRT decreases acute cell loss and late fibrosis after whole-abdomen and focal intestinal RT, whereas tumor growth inhibition is preserved between the 2 modalities., (Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
44. Early Tumor and Nodal Response in Patients with Locally Advanced Non-Small Cell Lung Carcinoma Predict for Oncologic Outcomes in Patients Treated with Concurrent Proton Therapy and Chemotherapy.
- Author
-
Grewal AS, Min EJ, Long Q, Grewal SK, Jain V, Levin WP, Cengel KA, Swisher-McClure S, Aggarwal C, Bauml JM, Singh A, Ciunci C, Cohen RB, Langer C, Feigenberg SJ, and Berman AT
- Subjects
- Adenocarcinoma diagnostic imaging, Adenocarcinoma mortality, Adenocarcinoma pathology, Adenocarcinoma radiotherapy, Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung mortality, Carcinoma, Non-Small-Cell Lung pathology, Carcinoma, Squamous Cell diagnostic imaging, Carcinoma, Squamous Cell mortality, Carcinoma, Squamous Cell pathology, Carcinoma, Squamous Cell radiotherapy, Four-Dimensional Computed Tomography, Humans, Kaplan-Meier Estimate, Lung Neoplasms mortality, Lung Neoplasms pathology, Lymph Nodes diagnostic imaging, Lymph Nodes pathology, Lymphatic Irradiation, Middle Aged, Progression-Free Survival, Radiotherapy Dosage, Remission Induction, Retrospective Studies, Time Factors, Treatment Outcome, Tumor Burden, Carcinoma, Non-Small-Cell Lung diagnostic imaging, Carcinoma, Non-Small-Cell Lung therapy, Chemoradiotherapy methods, Lung Neoplasms diagnostic imaging, Lung Neoplasms therapy, Proton Therapy
- Abstract
Purpose: There are no established imaging biomarkers that predict response during chemoradiation for patients with locally advanced non-small cell lung carcinoma. At our institution, proton therapy (PT) patients undergo repeat computed tomography (CT) simulations twice during radiation. We hypothesized that tumor regression measured on these scans would separate early and late responders and that early response would translate into better outcomes., Methods and Materials: Patients underwent CT simulations before starting PT (CT0) and between weeks 1 to 3 (CT1) and weeks 4 to 7 (CT2) of PT. Primary tumor volume (TVR) and nodal volume (NVR) reduction were calculated at CT1 and CT2. Based on recursive partitioning analysis, early response at CT1 and CT2 was defined as ≥20% and ≥40%, respectively. Locoregional and overall progression-free survival (PFS), distant metastasis-free survival, and overall survival by response status were measured using Kaplan-Meier analysis., Results: Ninety-seven patients with locally advanced non-small cell lung carcinoma underwent definitive PT to a median dose of 66.6 Gy with concurrent chemotherapy. Median TVR and NVR at CT1 were 19% (0-79%) and 19% (0-75%), respectively. At CT2, they were 33% (2-98%) and 35% (0-89%), respectively. With a median follow-up of 25 months, the median overall survival and PFS for the entire cohort was 24.9 and 13.2 months, respectively. Compared with patients with TVR and NVR <20% at T1 and <40% at T2, patients with TVR and NVR ≥20% at CT1 and ≥40% at CT2 had improved median locoregional PFS (27.15 vs 12.97 months for TVR ≥40% vs <40%, P < .01, and 25.67 vs 12.09 months for NVR ≥40% vs <40%, P < .01) and median PFS (22.7 vs 9.2 months, P < .01, and 20.3 vs 7.9 months, P < .01), confirmed on multivariate Cox regression analysis., Conclusions: Significantly improved outcomes in patients with early responses to therapy, as measured by TVR and NVR, were seen. Further study is warranted to determine whether treatment intensification will improve outcomes in slow-responding patients., (Copyright © 2019. Published by Elsevier Inc.)
- Published
- 2020
- Full Text
- View/download PDF
45. Risk of post-operative, pre-radiotherapy contralateral neck recurrence in patients treated with surgery followed by adjuvant radiotherapy for human papilloma virus-associated tonsil cancer.
- Author
-
Gershowitz J, Chao HH, Doucette A, Lukens JN, Swisher-McClure S, Weinstein GS, O'Malley BW Jr, Chalian AA, Rassekh CH, Newman JG, Cohen RB, Bauml JM, Aggarwal C, and Lin A
- Subjects
- Adult, Aged, Aged, 80 and over, Carcinoma, Squamous Cell pathology, Carcinoma, Squamous Cell virology, Female, Humans, Lymph Node Excision, Lymphatic Metastasis, Male, Margins of Excision, Middle Aged, Neoplasm Recurrence, Local, Odds Ratio, Papillomaviridae, Postoperative Period, Radiotherapy, Adjuvant methods, Radiotherapy, Intensity-Modulated, Regression Analysis, Retrospective Studies, Risk, Tonsillar Neoplasms pathology, Tonsillar Neoplasms virology, Tumor Burden, Carcinoma, Squamous Cell radiotherapy, Carcinoma, Squamous Cell surgery, Neoplasms, Second Primary etiology, Papillomavirus Infections complications, Tonsillar Neoplasms radiotherapy, Tonsillar Neoplasms surgery
- Abstract
Objective: One approach to reduce treatment-related morbidity for human papilloma virus (HPV)-associated tonsil cancer is omitting radiotherapy to the contralateral neck. Pathologic risk factors for early contralateral neck disease, however, are poorly understood. We report on the risk contralateral neck failures from the time of pre-operative diagnostic imaging to time of planning for adjuvant radiation in a single institution series of HPV-associated tonsillar cancer patients undergoing surgery followed by radiotherapy (RT)., Methods: Retrospective analysis of 123 patients with T1 - T3 HPV-positive tonsillar squamous cell carcinoma treated between 2010 and 2016 with transoral robotic surgery and selective ipsilateral neck dissection followed by adjuvant RT. Contralateral neck recurrence was classified as the detection of a pathologic node in the contralateral neck prior to initiation of adjuvant RT., Results: Seven patients (5.7%) developed contralateral neck disease/failure between the time of pre-operative diagnostic neck imaging and time of planning of adjuvant radiation. Increased ratio of positive/resected nodes [odds ratio (OR) 1.073, p = 0.005] was significantly associated with increased risk of contralateral neck recurrence, with a trend found for close/positive margins (OR 5.355, p = 0.06), tumor size (OR 2.046, p = 0.09), and total number of nodes positive (OR 1.179, p = 0.062)., Conclusions: Patients who develop very early contralateral neck disease, between completion of ipsilateral neck dissection and the initiation of radiotherapy, have a higher ratio of positive nodes to total nodes resected in the ipsilateral neck. These findings suggest that proper selection of patients for omission of treatment of the contralateral, node-negative neck should be made with this in mind, with future studies needed to document the impact on toxicity and disease outcomes from such an approach., Advances in Knowledge: Pathologic risk factors in the dissected, ipsilateral neck in patients with tonsil cancer may inform the risk of contralateral neck failure. Patient selection for future, prospective efforts to examine sparing of the contralateral neck need to be based with these risk factors in mind.
- Published
- 2019
- Full Text
- View/download PDF
46. The impact of treatment package time on locoregional control for HPV+ oropharyngeal squamous cell carcinoma treated with surgery and postoperative (chemo)radiation.
- Author
-
Chao HH, Schonewolf CA, Tan EX, Swisher-McClure S, Ghiam AF, Weinstein GS, O'Malley BW Jr, Chalian AA, Rassekh CH, Newman JG, Cohen RB, Bauml JM, Aggarwal C, Lin A, and Lukens JN
- Subjects
- Adult, Aged, Aged, 80 and over, Carcinoma, Squamous Cell pathology, Carcinoma, Squamous Cell virology, Combined Modality Therapy, Female, Humans, Male, Middle Aged, Oropharyngeal Neoplasms pathology, Oropharyngeal Neoplasms virology, Papillomavirus Infections complications, Papillomavirus Infections diagnosis, Retrospective Studies, Treatment Outcome, Carcinoma, Squamous Cell therapy, Duration of Therapy, Oropharyngeal Neoplasms therapy, Papillomavirus Infections therapy
- Abstract
Background: For patients with head and neck squamous cell carcinoma (SCC) undergoing surgery followed by postoperative radiotherapy (PORT), time from surgery to completion of adjuvant therapy, "package time" impacts locoregional control (LRC). However, the significance of package time in HPV+ oropharyngeal SCC (OPSCC) is unknown., Methods: We examined patients undergoing TORS resection with PORT for HPV+ OPSCC from January 2010 to December 2015 with ≥18 months follow-up (n = 267). A cutoff of 15 weeks was used to delineate patients into short and long package time groups. LRC loss was defined as any recurrence after surgery., Results: Prolonged package time >15 weeks was associated with inferior LRC in this HPV+ OPSCC cohort, driven primarily by interval from surgery to PORT initiation. Multivariate analysis showed that package time and T classification are both independently associated with LRC., Conclusions: Among HPV+ OPSCC, prolongation of package time appears to compromise LRC, but not survival., (© 2019 Wiley Periodicals, Inc.)
- Published
- 2019
- Full Text
- View/download PDF
47. It's the Team, Not the Beam.
- Author
-
Swisher-McClure S and Bekelman JE
- Subjects
- Insurance, Proton Therapy
- Published
- 2019
- Full Text
- View/download PDF
48. A prospective study of the feasibility of FDG-PET/CT imaging to quantify radiation-induced lung inflammation in locally advanced non-small cell lung cancer patients receiving proton or photon radiotherapy.
- Author
-
Jahangiri P, Pournazari K, Torigian DA, Werner TJ, Swisher-McClure S, Simone CB 2nd, and Alavi A
- Subjects
- Feasibility Studies, Female, Fluorodeoxyglucose F18, Humans, Male, Proton Therapy adverse effects, Radiation Pneumonitis etiology, Radiopharmaceuticals, Carcinoma, Non-Small-Cell Lung radiotherapy, Lung Neoplasms radiotherapy, Photons adverse effects, Positron Emission Tomography Computed Tomography standards, Radiation Pneumonitis diagnostic imaging
- Abstract
Purpose: This prospective study assessed the feasibility of
18 F-2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography/computed tomography (PET/CT) to quantify radiation-induced lung inflammation in patients with locally advanced non-small cell lung cancer (NSCLC) who received radiotherapy (RT), and compared the differences in inflammation in the ipsilateral and contralateral lungs following proton and photon RT., Methods: Thirty-nine consecutive patients with NSCLC underwent FDG-PET/CT imaging before and after RT on a prospective study. A novel quantitative approach utilized regions of interest placed around the anatomical boundaries of the lung parenchyma and provided lung mean standardized uptake value (SUVmean), global lung glycolysis (GLG), global lung parenchymal glycolysis (GLPG) and total lung volume (LV). To quantify primary tumor metabolic response to RT, an adaptive contrast-oriented thresholding algorithm was applied to measure metabolically active tumor volume (MTV), tumor uncorrected SUVmean, tumor partial volume corrected SUVmean (tumor-PVC-SUVmean), and total lesion glycolysis (TLG). Parameters of FDG-PET/CT scans before and after RT were compared using two-tailed paired t-tests., Results: All tumor parameters after either proton or photon RT decreased significantly (p < 0.001). Among the 21 patients treated exclusively with proton RT, no significant increase in PVC-SUVmean or PVC-GLPG was observed in ipsilateral lungs after the PVC parameters of primary tumor were subtracted (p = 0.114 and p = 0.453, respectively). Also, there were no significant increases in SUVmean or GLG of contralateral lungs of patients who received proton RT (p = 0.841, p = 0.241, respectively). In contrast, among the nine patients who received photon RT, there was a statistically significant increase in PVC-GLPG of ipsilateral lung (p < 0.001) and in GLG of contralateral (p = 0.036) lung. In the subset of nine patients who received a combined proton and photon RT, there was a statistically significant increase in PVC-GLPG of ipsilateral lung (p < 0.001)., Conclusion: Our data suggest less induction of inflammatory response in both the ipsilateral and contralateral lungs of patients treated with proton compared to photon or combined proton-photon RT.- Published
- 2019
- Full Text
- View/download PDF
49. Utilization of hypofractionated radiation therapy in older glioblastoma patients.
- Author
-
Nead KT and Swisher-McClure S
- Subjects
- Age Factors, Aged, Aged, 80 and over, Brain Neoplasms mortality, Chi-Square Distribution, Female, Glioblastoma mortality, Humans, Logistic Models, Male, Propensity Score, Radiation Dose Hypofractionation, Retrospective Studies, Survival Analysis, Brain Neoplasms radiotherapy, Dose Fractionation, Radiation, Glioblastoma radiotherapy
- Abstract
Background: Though the optimal treatment regimen in older patients with glioblastoma multiforme (GBM) remains to be established, multiple randomized studies have supported the use of hypofractionated (1-3 weeks) versus traditional regimens (6 weeks). Here we examine hypofractionated regimen practice patterns among older patients with GBM., Methods: We used the National Cancer Database and included individuals aged ≥65 years with GBM diagnosed from 2005 to 2014 undergoing biopsy/resection followed by chemotherapy and radiation initiated ≤8-weeks of diagnosis. We defined traditional fractionation as ≤200 cGy and hypofractionation as >200 cGy. We compared patient characteristics using a chi-squared test and multivariable logistic regression. We compared 90-day mortality rates following initiation of radiation using the Wald statistic in propensity score matched cohorts., Results: The final cohort included 14,931 individuals with 1524 undergoing hypofractionated treatment. From 2005 to 2014 hypofractionated utilization rates were 7%, 9%, 13%, and 18% among those 65-69, 70-74, 75-79, and ≥80 years of age, respectively. Patients treated at an academic/research center had a >60% increased odds (OR, 1.61; 95% CI, 1.43-1.81) of undergoing hypofractionated regimens versus a community center. Ninety-day mortality rates were high in both groups (hypofractionated: 32%; traditional: 24%; p < .001)., Conclusions: The majority of older GBM patients do not undergo hypofractionated radiation. High 90-day mortality in both groups suggests that hypofractionation may improve the survival-to-treatment time ratio and positively impact patient quality of life. Hypofractionated radiation regimens for GBM should be discussed with older patients and considered for inclusion in efforts to improve the quality and value of cancer care., (Copyright © 2018 Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
50. Reduced Cancer Survival Among Adults With HIV and AIDS-Defining Illnesses Despite No Difference in Cancer Stage at Diagnosis.
- Author
-
Grover S, Desir F, Jing Y, Bhatia RK, Trifiletti DM, Swisher-McClure S, Kobie J, Moore RD, Rabkin CS, Silverberg MJ, Salters K, Mathews WC, Gill MJ, Thorne JE, Castilho J, Kitahata MM, Justice A, Horberg MA, Achenbach CJ, Mayor AM, and Althoff KN
- Subjects
- Adult, Female, Humans, Male, Middle Aged, Neoplasm Staging, Survival Analysis, HIV Infections complications, Neoplasms mortality, Neoplasms pathology
- Abstract
Background: It is not known whether immune dysfunction is associated with increased risk of death after cancer diagnosis in persons with HIV (PWH). AIDS-defining illness (ADI) can signal significant immunosuppression. Our objective was to determine differences in cancer stage and mortality rates in PWH with and without history of ADI., Methods: PWH with anal, oropharynx, cervical, lung cancers, or Hodgkin lymphoma diagnoses from January 2000 to December 2009 in the North American AIDS Cohort Collaboration on Research and Design were included., Results: Among 81,865 PWH, 814 had diagnoses included in the study; 341 (39%) had a history of ADI at time of cancer diagnosis. For each cancer type, stage at diagnosis did not differ by ADI (P > 0.05). Mortality and survival estimates for cervical cancer were limited by n = 5 diagnoses. Adjusted mortality rate ratios showed a 30%-70% increase in mortality among those with ADI for all cancer diagnoses, although only lung cancer was statistically significant. Survival after lung cancer diagnosis was poorer in PWH with ADI vs. without (P = 0.0001); the probability of survival was also poorer in those with ADI at, or before other cancers although not statistically significant., Conclusions: PWH with a history of ADI at lung cancer diagnosis had higher mortality and poorer survival after diagnosis compared to those without. Although not statistically significant, the findings of increased mortality and decreased survival among those with ADI (vs. without) were consistent for all other cancers, suggesting the need for further investigations into the role of HIV-related immune suppression and cancer outcomes.
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.